Anticorps de l'hépatite : Questions médicales fréquentes
Nom anglais: Hepatitis Antibodies
Descriptor UI:D006508
Tree Number:D12.776.377.715.548.114.254.450
Termes MeSH sélectionnés :
Developing Countries
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite : Questions médicales les plus fréquentes",
"headline": "Anticorps de l'hépatite : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps de l'hépatite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Anticorps antiviraux",
"url": "https://questionsmedicales.fr/mesh/D000914",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D000914",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite A",
"alternateName": "Hepatitis A Antibodies",
"url": "https://questionsmedicales.fr/mesh/D035922",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D035922",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.251"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite B",
"alternateName": "Hepatitis B Antibodies",
"url": "https://questionsmedicales.fr/mesh/D006510",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D006510",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.504"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite C",
"alternateName": "Hepatitis C Antibodies",
"url": "https://questionsmedicales.fr/mesh/D018937",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite C",
"code": {
"@type": "MedicalCode",
"code": "D018937",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite",
"alternateName": "Hepatitis Antibodies",
"code": {
"@type": "MedicalCode",
"code": "D006508",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mansun Law",
"url": "https://questionsmedicales.fr/author/Mansun%20Law",
"affiliation": {
"@type": "Organization",
"name": "Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92109, USA."
}
},
{
"@type": "Person",
"name": "Michiko Koga",
"url": "https://questionsmedicales.fr/author/Michiko%20Koga",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Makoto Saito",
"url": "https://questionsmedicales.fr/author/Makoto%20Saito",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Eisuke Adachi",
"url": "https://questionsmedicales.fr/author/Eisuke%20Adachi",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Amato Otani",
"url": "https://questionsmedicales.fr/author/Amato%20Otani",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37428216",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00259-023-06332-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between the use of Sci-Hub and consultation of scientific journals by medical students from six Latin American countries: A secondary analysis.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37600382",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2023.e17868"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interventions targeting the mental health and wellbeing of care-experienced children and young people in higher-income countries: Evidence map and systematic review.",
"datePublished": "2023-07-01",
"url": "https://questionsmedicales.fr/article/37393358",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13643-023-02260-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.",
"datePublished": "2023-06-30",
"url": "https://questionsmedicales.fr/article/37386452",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-023-11074-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plastic Venture Builder (PVB): An empirically derived assessment tool to support plastic waste management ventures in low- and middle-income countries.",
"datePublished": "2023-06-30",
"url": "https://questionsmedicales.fr/article/37386896",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/0734242X231180648"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
},
{
"@type": "ListItem",
"position": 8,
"name": "Anticorps antiviraux",
"item": "https://questionsmedicales.fr/mesh/D000914"
},
{
"@type": "ListItem",
"position": 9,
"name": "Anticorps de l'hépatite",
"item": "https://questionsmedicales.fr/mesh/D006508"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps de l'hépatite - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps de l'hépatite",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps de l'hépatite",
"description": "Comment détecte-t-on les anticorps de l'hépatite ?\nQuels types d'anticorps sont testés ?\nQuand faut-il faire un test d'anticorps ?\nLes anticorps indiquent-ils une infection active ?\nPeut-on avoir des anticorps sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps de l'hépatite",
"description": "Quels sont les symptômes de l'hépatite A ?\nL'hépatite B présente-t-elle des symptômes ?\nQuels symptômes sont associés à l'hépatite C ?\nLes symptômes de l'hépatite D sont-ils similaires ?\nQuels signes indiquent une hépatite E ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps de l'hépatite",
"description": "Comment prévenir l'hépatite A ?\nQuelles mesures pour l'hépatite B ?\nL'hépatite C peut-elle être évitée ?\nY a-t-il un vaccin pour l'hépatite E ?\nComment réduire le risque d'hépatite D ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps de l'hépatite",
"description": "Comment traite-t-on l'hépatite A ?\nQuels traitements existent pour l'hépatite B ?\nL'hépatite C peut-elle être guérie ?\nY a-t-il un vaccin pour l'hépatite B ?\nComment gérer l'hépatite D ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps de l'hépatite",
"description": "Quelles complications peuvent survenir avec l'hépatite B ?\nL'hépatite C peut-elle causer des complications ?\nQuelles sont les complications de l'hépatite D ?\nL'hépatite A entraîne-t-elle des complications ?\nQuelles complications sont liées à l'hépatite E ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps de l'hépatite",
"description": "Quels sont les facteurs de risque pour l'hépatite A ?\nQuels comportements augmentent le risque d'hépatite B ?\nQui est à risque pour l'hépatite C ?\nLes travailleurs de la santé sont-ils à risque d'hépatite ?\nLes personnes vivant avec le VIH sont-elles à risque d'hépatite ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les anticorps de l'hépatite ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des tests sanguins spécifiques qui mesurent les anticorps présents."
}
},
{
"@type": "Question",
"name": "Quels types d'anticorps sont testés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticorps anti-HAV, anti-HBV, anti-HCV, anti-HEV, et anti-HDV."
}
},
{
"@type": "Question",
"name": "Quand faut-il faire un test d'anticorps ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après une exposition suspectée ou en cas de symptômes d'hépatite."
}
},
{
"@type": "Question",
"name": "Les anticorps indiquent-ils une infection active ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, certains anticorps indiquent une infection passée ou une immunité."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des anticorps sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être asymptomatiques tout en ayant des anticorps."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hépatite A ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, nausées, douleurs abdominales, jaunisse."
}
},
{
"@type": "Question",
"name": "L'hépatite B présente-t-elle des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être asymptomatique ou provoquer fatigue, douleurs articulaires, jaunisse."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à l'hépatite C ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, douleurs abdominales, jaunisse, mais souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les symptômes de l'hépatite D sont-ils similaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils ressemblent à ceux de l'hépatite B, avec des complications possibles."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hépatite E ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, nausées, et jaunisse, surtout dans les zones à risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hépatite A ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vaccination, hygiène alimentaire, et lavage des mains sont essentiels."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour l'hépatite B ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vaccination, éviter le partage d'aiguilles et rapports protégés."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle être évitée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le partage d'aiguilles et pratiquer des rapports protégés aide à prévenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite E ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin commercialisé pour l'hépatite E."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque d'hépatite D ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Prévenir l'hépatite B par vaccination réduit le risque d'hépatite D."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on l'hépatite A ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de traitement spécifique, repos et hydratation sont recommandés."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'hépatite B ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Antiviraux comme la lamivudine ou l'interféron peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle être guérie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec des antiviraux à action directe, la guérison est possible."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite B ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un vaccin efficace est disponible pour prévenir l'hépatite B."
}
},
{
"@type": "Question",
"name": "Comment gérer l'hépatite D ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement de l'hépatite B est essentiel, car l'hépatite D dépend de celle-ci."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hépatite B ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cirrhose, cancer du foie, et insuffisance hépatique sont des complications possibles."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut mener à la cirrhose et au cancer du foie sur le long terme."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hépatite D ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut aggraver l'hépatite B, entraînant des complications hépatiques sévères."
}
},
{
"@type": "Question",
"name": "L'hépatite A entraîne-t-elle des complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des cas graves peuvent survenir, surtout chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à l'hépatite E ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Peuvent inclure des cas graves chez les femmes enceintes, comme l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'hépatite A ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Voyages dans des zones à risque, consommation d'eau contaminée, et aliments crus."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque d'hépatite B ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partage d'aiguilles, rapports non protégés, et transfusions sanguines non testées."
}
},
{
"@type": "Question",
"name": "Qui est à risque pour l'hépatite C ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les consommateurs de drogues injectables et les personnes ayant des rapports à risque."
}
},
{
"@type": "Question",
"name": "Les travailleurs de la santé sont-ils à risque d'hépatite ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont exposés à des fluides corporels et doivent suivre des protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Les personnes vivant avec le VIH sont-elles à risque d'hépatite ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles ont un risque accru d'infections par les virus de l'hépatite."
}
}
]
}
]
}
The proPSMA trial at ten Australian centers demonstrated increased sensitivity and specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status in primary high-risk prostat...
Clinical data on diagnostic accuracy were derived from the proPSMA trial. Costs for PSMA PET/CT and conventional imaging were taken from reimbursements of national health systems and individual billin...
In contrast to the Australian setting, PSMA PET/CT was primarily associated with increased costs in the studied centers in Europe and the USA. Mainly, the scan duration had an impact on the cost-effec...
We assume that the use of PSMA PET/CT is appropriate from a health economic perspective, but this will need to be verified by a prospective evaluation of patients at initial diagnosis....
Sci-Hub is a website that allows users to download full-text versions of millions of scientific articles for free. The objective of this study was to evaluate the association between the use of Sci-Hu...
We conducted a secondary analysis of data from a 2017 cross-sectional study of medical students from six Latin American countries (Argentina, Bolivia, Chile, Colombia, Paraguay, and Peru). Consultatio...
Of the 6632 participants, 38.2% consulted scientific journals and 10.3% used Sci-Hub once a week. Using Sci-Hub at least once a week was associated with a 20% increase in the prevalence of consulting ...
Amongst medical students surveyed from the above six Latin American countries, the use of Sci-Hub at least once a week was significantly associated with the self-reported prevalence of consulting scie...
The mental health and wellbeing of care-experienced children and young people (i.e. foster care, kinship care, residential care) is poorer than non-care-experienced populations. The Care-experienced c...
For the first phase of the review, we constructed an evidence map identifying key clusters and gaps in interventions and evaluations. Studies were identified through 16 electronic databases and 22 hea...
In total, 64 interventions with 124 associated study reports were eligible. The majority of study reports were from the USA (n = 77). Interventions primarily targeted children and young people's skill...
Future intervention development might focus on structural-level intervention theories and components, and target outcomes related to subjective wellbeing and suicide. In accordance with current method...
PROSPERO CRD42020177478....
The landscape of non-small cell lung cancer (NSCLC) therapy is rapidly changing. This analysis aimed to understand patient characteristics, diagnosis and treatment patterns in patients with metastatic...
Data were drawn from the Adelphi NSCLC Disease Specific Programme™, a point-in-time survey of oncologists/pulmonologists and their consulting patients in France, Germany, Italy, Spain and UK. Physicia...
Mean (standard deviation [SD]) age for 1073 patients with EGFR-wild-type/ALK-wild-type mNSCLC was 66.2 (8.9) years, 65.2% were male and 63.7% had adenocarcinoma. Level of PD-L1 expression at advanced ...
Real-world treatment patterns suggest that chemotherapy use remains high despite guidelines recommending immunotherapy-based 1L treatment for mNSCLC. QoL reported by patients was generally lower than ...
Plastic waste management is a complicated challenge that in recent years has gained attention as a global policy priority. In low- and middle-income countries (LMIC), waste management is heterogeneous...
Positive health technology assessment (HTA) outcomes can have important implications for equity, efficiency and timely patient access to novel therapies. Several outcomes and dimensions of benefit bey...
We analyse a proprietary dataset of HTA outcomes in 7 countries, to (a) test whether HTA decision-making is grounded in welfarist or extra-welfarist approaches; and (b) empirically determine the facto...
Data were extracted from publicly available HTA reports on drugs that received marketing authorisation between 2009 and 2018 (N = 1415). The outcomes of interest were the probability of positive HTA o...
Positive HTA outcomes accounted for 87.3% of the sample (n = 1235), of which 71% (n = 1004) were restricted. Drugs with positive HTA outcomes were subject to clinical restrictions (n = 652, 46%), fina...
Our results are contextual and reinforce arguments in favour of explicitly accounting for social value judgements, establishing separate assessment frameworks for highly uncertain products, adopting r...
Most people who develop chronic diseases, including cardiovascular disease (CVD), live in their homes in the community in their last year of life. Since cost-sharing is common in most countries, inclu...
SHARE data among people aged 50 + from seven European countries (including Israel) who died from CVD are analyzed. Decedents' family members are interviewed to learn about OOPE on their relatives' acc...
We identified 1,335 individuals who had died from CVD (average age 80.8 years, 54% men). More than half of CVD-decedent people spend OOPE on community services at EOL and their expenditure varies wide...
Since improving CVD care efficiency and effectiveness are key aims, healthcare policymakers should broaden the investigation into expanding public funding for community services in order to mitigate O...
Possible sex differences in hepatitis A virus (HAV) incidence rates in different age groups are not well documented. We aimed to obtain stable pooled estimates of such differences based on data from a...
We obtained data on incident cases of HAV by sex and age group over a period of 6-25 years from nine countries: Australia, Canada, Czech Republic, Finland, Germany, Israel, Netherland, New Zealand and...
A male excess in incidence rates was consistently observed in all age groups, although in the youngest and oldest age groups, where the numbers tended to be lower, the lower bounds of the 95% confiden...
The excess HAV incidence rates in young males, pooled over a number of countries, suggest that the sex differences are likely to be due at least in part to physiological and biological differences and...
Due to its widespread use in the sex work industry, female sex workers (FSWs) in low- and middle-income countries (LMICs) are at high risk of harmful alcohol use and associated adverse health outcomes...
To understand the role of different school-wide practices in school-wide bullying prevention in the global context, this present study was guided by the social-ecological framework to examine cross-co...